New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges PDF Download

Author: Ahmed Bakillah
Publisher: MDPI
ISBN: 3039216767
Category : Science
Languages : en
Pages : 116

View

Book Description
This book illustrates some of the most recent research efforts that have been made in lowering plasma cholesterol levels in patients with CVD. Selected articles aimed to illuminate advances and urgent challenges in the management of CVD, including disease management using statin-combined therapeutic strategies.

Author: Shirya Rashid
Publisher: Academic Press
ISBN: 9780323900560
Category : Medical
Languages : en
Pages : 160

View

Book Description
In the last few decades, statins had been widely used to successfully lower ASCVD risk. Despite the efficacy of statins in reducing CVD events in primary and secondary prevention patients, there is still substantial residual risk and initial and recurring CVD events remaining in these patient groups. Dyslipidemia Therapies for Reducing Cardiovascular Disease Risk provides an overview of the latest research and developments in dyslipidemia therapies to combat elevated lipid levels leading to atherosclerotic cardiovascular disease (ASCVD). A translational medicine approach is used to discuss the background on key lipid disorders in the population leading to cardiovascular disease; clinical trial development of the new drug therapies to combat the lipid disorders and their mechanisms of action; and the target patient groups of the therapies and how they address unmet medical needs in cardiovascular disease/lipid disorders. Contributions from leaders in the dyslipidemia, metabolic and cardiology fields, they offer insights into the research and development and medical backgrounds of the new drug therapies, as well as unpublished information regarding the challenges in unmet medical needs with respect to dyslipidemia in the population, clinical trial development of the therapies and future goals for the therapies. Fills the knowledge gap in the range and prevalence of dyslipiddemias in the population - both common and rare dyslipdemias - and the appropriate current therapies to manage these lipid disorders Get up-to-date with the rapidly evolving research/translational medicine, clinical trials for new and emerging therapies on the horizon and new FDA approved drugs being implemented globally Thought leaders in the field provides unpublished insights on the dyslipidemia field, its challenges and goals and what's in the horizon for patient therapies and, further, the best approach to use for patient management in this complex area of cardiology

Author:
Publisher:
ISBN:
Category : Coronary heart disease
Languages : en
Pages : 2

View

Book Description

Author: Scott M. Grundy
Publisher: CRC Press
ISBN: 9780367399320
Category :
Languages : en
Pages : 352

View

Book Description
Reveals important new results from clinical trials conducted in Scandinavia, Scotland, Australia, Canada, and the United States. This timely reference reviews the vast body of clinical trial evidence supporting the once controversial view that high levels of serum cholesterol are a major risk factor in coronary heart disease (CHD). The studies presented in Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence promote cholesterol reduction as a highly successful means of preventing heart disease in various populations. Investigates past, current, and upcoming controlled clinical trials of cholesterol-reduction therapies, comparing effects of statins and bile acid sequestrants to triglyceride-lowering drugs and antioxidants. Written by more than 25 distinguished international researchers, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence highlights historical studies of dietary trials designed to reduce CHD covers tests of HMG CoA reductase inhibitors for patients with and without CHD illuminates CHD risk factors such as diabetes, hypertension, obesity, and smoking explores blood levels of homocysteine and lipoprotein(a) and other recently identified CHD risk factors reviews metabolism of lipoproteins expressed in high (HDL) and low (LDL) density lipoprotein cholesterol and more! Containing over 700 instructive tables, drawings, photographs, and bibliographic citations, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence is a must-read resource for cardiologists, pharmacologists, and upper-level undergraduate, graduate, and medical school students in these disciplines.

Author: National Cholesterol Education Program (U.S.). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Publisher:
ISBN:
Category : Blood cholesterol
Languages : en
Pages : 182

View

Book Description

Author: Dorairaj Prabhakaran
Publisher: World Bank Publications
ISBN: 1464805202
Category : Medical
Languages : en
Pages : 948

View

Book Description
Cardiovascular, respiratory, and related conditions cause more than 40 percent of all deaths globally, and their substantial burden is rising, particularly in low- and middle-income countries (LMICs). Their burden extends well beyond health effects to include significant economic and societal consequences. Most of these conditions are related, share risk factors, and have common control measures at the clinical, population, and policy levels. Lives can be extended and improved when these diseases are prevented, detected, and managed. This volume summarizes current knowledge and presents evidence-based interventions that are effective, cost-effective, and scalable in LMICs.

Author: National Research Council
Publisher: National Academies Press
ISBN: 0309039940
Category : Medical
Languages : en
Pages : 765

View

Book Description
Diet and Health examines the many complex issues concerning diet and its role in increasing or decreasing the risk of chronic disease. It proposes dietary recommendations for reducing the risk of the major diseases and causes of death today: atherosclerotic cardiovascular diseases (including heart attack and stroke), cancer, high blood pressure, obesity, osteoporosis, diabetes mellitus, liver disease, and dental caries.

Author: Naranjan S. Dhalla
Publisher: Springer
ISBN: 9781461350842
Category : Medical
Languages : en
Pages : 648

View

Book Description
Pathophysiology of Cardiovascular Disease has been divided into four sections that focus on heart dysfunction and its associated characteristics (hypertrophy, cardiomyopathy and failure); vascular dysfunction and disease; ischemic heart disease; and novel therapeutic interventions. This volume is a compendium of different approaches to understanding cardiovascular disease and identifying the proteins, pathways and processes that impact it.

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 030921646X
Category : Medical
Languages : en
Pages : 217

View

Book Description
Advances in medical, biomedical and health services research have reduced the level of uncertainty in clinical practice. Clinical practice guidelines (CPGs) complement this progress by establishing standards of care backed by strong scientific evidence. CPGs are statements that include recommendations intended to optimize patient care. These statements are informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options. Clinical Practice Guidelines We Can Trust examines the current state of clinical practice guidelines and how they can be improved to enhance healthcare quality and patient outcomes. Clinical practice guidelines now are ubiquitous in our healthcare system. The Guidelines International Network (GIN) database currently lists more than 3,700 guidelines from 39 countries. Developing guidelines presents a number of challenges including lack of transparent methodological practices, difficulty reconciling conflicting guidelines, and conflicts of interest. Clinical Practice Guidelines We Can Trust explores questions surrounding the quality of CPG development processes and the establishment of standards. It proposes eight standards for developing trustworthy clinical practice guidelines emphasizing transparency; management of conflict of interest ; systematic review-guideline development intersection; establishing evidence foundations for and rating strength of guideline recommendations; articulation of recommendations; external review; and updating. Clinical Practice Guidelines We Can Trust shows how clinical practice guidelines can enhance clinician and patient decision-making by translating complex scientific research findings into recommendations for clinical practice that are relevant to the individual patient encounter, instead of implementing a one size fits all approach to patient care. This book contains information directly related to the work of the Agency for Healthcare Research and Quality (AHRQ), as well as various Congressional staff and policymakers. It is a vital resource for medical specialty societies, disease advocacy groups, health professionals, private and international organizations that develop or use clinical practice guidelines, consumers, clinicians, and payers.

Author: Paul D. Thompson
Publisher: Springer Nature
ISBN: 3030333043
Category : Medical
Languages : en
Pages : 191

View

Book Description
This book provides an overview of statin-associated muscle symptoms (SAMS) from clinical presentation to treatment and possible metabolic causes. It examines the risk factors, presentations, diagnosis and differential diagnosis, clinical management, and financial costs of SAMS. The book also highlights patients’ perspectives on SAMS such as the psychosocial, emotional, and societal factors influencing their perceptions and experiences. Finally, the book presents the results of observational and clinical trials on the prevalence of SAMS, clinical trials for treatments, and potential future research approaches for improving the understanding and treatment of SAMS. A key addition to the Contemporary Cardiology series, Statin-Associated Muscle Symptoms is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in cardiology, endocrinology, pharmacotherapy, primary care, and health promotion and disease prevention.